- Application under evaluation
- CVMP opinion
- European Commission decision
Overview
Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website.
Versican Plus Pi/L4 : EPAR - Summary for the public
English (EN) (81.94 KB - PDF)
български (BG) (93.36 KB - PDF)
español (ES) (81.97 KB - PDF)
čeština (CS) (93.99 KB - PDF)
dansk (DA) (83.34 KB - PDF)
Deutsch (DE) (82.76 KB - PDF)
eesti keel (ET) (82.18 KB - PDF)
ελληνικά (EL) (93.76 KB - PDF)
français (FR) (82.44 KB - PDF)
hrvatski (HR) (92.27 KB - PDF)
íslenska (IS) (83.29 KB - PDF)
Gaeilge (GA) (83.57 KB - PDF)
italiano (IT) (82.29 KB - PDF)
latviešu valoda (LV) (94.29 KB - PDF)
lietuvių kalba (LT) (94.03 KB - PDF)
magyar (HU) (94.15 KB - PDF)
Malti (MT) (95.95 KB - PDF)
Nederlands (NL) (82.05 KB - PDF)
norsk (NO) (82 KB - PDF)
polski (PL) (95.62 KB - PDF)
português (PT) (83.01 KB - PDF)
română (RO) (94.17 KB - PDF)
slovenčina (SK) (94.08 KB - PDF)
slovenščina (SL) (82.27 KB - PDF)
Suomi (FI) (81.54 KB - PDF)
svenska (SV) (82.05 KB - PDF)
Product information
Versican Plus Pi/L4 : EPAR - Product Information
English (EN) (81.49 KB - PDF)
български (BG) (91.78 KB - PDF)
español (ES) (81.51 KB - PDF)
čeština (CS) (92.48 KB - PDF)
dansk (DA) (82.05 KB - PDF)
Deutsch (DE) (81.72 KB - PDF)
eesti keel (ET) (81.22 KB - PDF)
ελληνικά (EL) (91.79 KB - PDF)
français (FR) (81.63 KB - PDF)
hrvatski (HR) (91.56 KB - PDF)
íslenska (IS) (81.52 KB - PDF)
Gaeilge (GA) (81.36 KB - PDF)
italiano (IT) (81.76 KB - PDF)
latviešu valoda (LV) (92.14 KB - PDF)
lietuvių kalba (LT) (92.19 KB - PDF)
magyar (HU) (92.76 KB - PDF)
Malti (MT) (93.86 KB - PDF)
Nederlands (NL) (81.15 KB - PDF)
norsk (NO) (81.52 KB - PDF)
polski (PL) (93.22 KB - PDF)
português (PT) (82.53 KB - PDF)
română (RO) (91.73 KB - PDF)
slovenčina (SK) (81.75 KB - PDF)
slovenščina (SL) (81.76 KB - PDF)
Suomi (FI) (81.11 KB - PDF)
svenska (SV) (81.47 KB - PDF)
Versican Plus Pi/L4 : EPAR - All Authorised presentations
English (EN) (81.94 KB - PDF)
български (BG) (93.36 KB - PDF)
español (ES) (81.97 KB - PDF)
čeština (CS) (93.99 KB - PDF)
dansk (DA) (83.34 KB - PDF)
Deutsch (DE) (82.76 KB - PDF)
eesti keel (ET) (82.18 KB - PDF)
ελληνικά (EL) (93.76 KB - PDF)
français (FR) (82.44 KB - PDF)
hrvatski (HR) (92.27 KB - PDF)
íslenska (IS) (83.29 KB - PDF)
Gaeilge (GA) (83.57 KB - PDF)
italiano (IT) (82.29 KB - PDF)
latviešu valoda (LV) (94.29 KB - PDF)
lietuvių kalba (LT) (94.03 KB - PDF)
magyar (HU) (94.15 KB - PDF)
Malti (MT) (95.95 KB - PDF)
Nederlands (NL) (82.05 KB - PDF)
norsk (NO) (82 KB - PDF)
polski (PL) (95.62 KB - PDF)
português (PT) (83.01 KB - PDF)
română (RO) (94.17 KB - PDF)
slovenčina (SK) (94.08 KB - PDF)
slovenščina (SL) (82.27 KB - PDF)
Suomi (FI) (81.54 KB - PDF)
svenska (SV) (82.05 KB - PDF)
Product details
- Name of medicine
- Versican Plus Pi/L4
- Active substance
- Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 (live attenuated), Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088, L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain MSLB 1089, L. interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 and L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 (all inactivated)
- International non-proprietary name (INN) or common name
- canine parainfluenza virus and Leptospira
Authorisation details
- EMA product number
- EMEA/V/C/003683
Assessment history
Versican Plus Pi/L4 : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (81.49 KB - PDF)
CVMP summary of positive opinion for Versican Plus Pi/L4
English (EN) (78.08 KB - PDF)